KGK Synergize has taken back the global distribution rights for its cholesterol lowering Sytrinol ingredient, but the company said supply to customers would not be impacted by the move.
KGK Synergize has a full pipeline of new nutraceutical products,
and is seeking additional growth capital of between C$7 and $10m to
bring them to market over the coming years.